Biotron to Present Latest Clinical Trial on HIV-1 Data at CROI

December 02, 2019 06:34 PM PST | By Team Kalkine Media

Google News:

Recent News

Medtronic’s Steady Growth Within NYSE Composite Reflects Strong Operat...

NVIDIA Rallies on Sector Strength and Momentum Within Nasdaq Composite...

Is (NASDAQ:VC) Undervalued as Nasdaq Composite Reflects Broader Market...

First Trust Financials AlphaDEX becomes the largest shareholders of Fr...

Biotron LimitedÂ (ASX:BIT) would be presenting its latest clinical trial data at the Conference on Retroviral and Opportunistic Infections (âCROIâ), to be held in Boston MA, USA in March 2020.

Ever since the company completed the BIT225-009 Phase 2 HIV-1 clinical trial, Biotron has continued to characterise the unique mechanism of action of its lead antiviral drug, BIT225.

BIT225 induces the significant beneficial immunological changes observed in the completed Phase 2 clinical trial and form the basis of the paper to be presented at CROI. The Directors has also announced that the new data from the Phase 2 trial, resulting from these post-trial analyses, have significantly enhanced the companyâs intellectual property position.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.